Facts and fiction: Premalignant lesions of lung tissues

Pathology

Volumn 45, Issue 3, 2013, Pages 305-315

  Klebe, S ^a   Henderson, D W ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Carcinogenesis; Lung cancer; Preneoplastic lesion

Indexed keywords

EID: 84879362070     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835f45fd     Document Type: Article

References (78)

1. Kerr K, Fraire A. Preinvasive disease. In: Tomashefski JF Jr. Dail and Hammar's Pulmonary Pathology. New York: Springer, 2008, 158-215.
2. Cancer Council Australia. Lung cancer. 9 Feb 2012 (cited Nov 2012). http://www.cancer.org.au/about-cancer/types-of-cancer/lung-cancer.html.
3. Aberle DR, Gamsu G, Henschke CI, et al. A consensus statement of the Society of Thoracic Radiology: screening for lung cancer with helical computed tomography. J Thorac Imaging 2001; 16: 65-8.
4. Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci 2001; 952: 124-34.
5. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004.
6. Wang GF, Lai MD, Yang RR, et al. Histological types and significance of bronchial epithelial dysplasia. Mod Pathol 2006; 19: 429-37.
7. Cook JR, Hill DA, Humphrey PA, et al. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol 2000; 13: 914-8.
8. Katsenos S, Becker HD. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol 2011; 4: 162-71.
9. Lin HW, Richmon JD, Emerick KS, et al. Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol 2010; 31: 291-6.
10. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998; 110: 397-404.
11. Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 1992; 9: 151-61.
12. Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 2011; 74: 7-11.
13. Dacic S. Pulmonary preneoplasia. Arch Pathol Lab Med 2008; 132: 1073-8.
14. Lantuejoul S, Salameire D, Salon C, Brambilla E. Pulmonary preneoplasia-sequential molecular carcinogenetic events. Histopathology 2009; 54: 43-54.
15. Wistuba II. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 2007; 7: 3-14.
16. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006; 1: 331-48.
17. Simon F, Johnen G, Krismann M, Muller KM. Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch 2005; 447: 762-7.
18. Petty TL. The early identification of lung carcinoma by sputum cytology. Cancer 2000; 89: 2461-4.
19. Gustafson AM, Soldi R, Anderlind C, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010; 2: 26ra5.
20. Ishizumi T, McWilliams A, MacAulay C, et al. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev 2010; 29: 5-14.
21. Roa WH, Kim JO, Razzak R, et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012; 35: E271.
22. Fanini F, Vannini I, Amadori D, Fabbri M. Clinical implications of microRNAs in lung cancer. Semin Oncol 2011; 38: 776-80.
23. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127: 2870-8.
24. Oda S, Awai K, Liu D, et al. Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol 2008; 190: 1363-8.
25. Lee HY, Lee KS. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging 2008; 26: 106-18.
26. Min JH, Lee HY, Lee KS, et al. Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. Lung Cancer 2010; 69: 123-6.
27. Ruffini E, Bongiovanni M, Cavallo A, et al. The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms. Eur J Cardiothorac Surg 2004; 26: 165-72.
28. Gorshtein A, Gross DJ, Barak D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer 2012; 118: 612-9.
29. Nassar AA, Jaroszewski DE, Helmers RA, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med 2012; 184: 8-16.
30. Pankiewicz W, Minarowski L, Niklinska W, et al. Immunohistochemical markers of cancerogenesis in the lung. Folia Histochem Cytobiol 2007; 45: 65-74.
31. Singh AP, Pant MC, Ruwali M, et al. Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark 2010-2011; 8: 351-9.
32. Ji YN, Wang Q, Lin XQ, Suo LJ. CYP1A1 MspI polymorphisms and lung cancer risk: an updated meta-analysis involving 20, 209 subjects. Cytokine 2012; 59: 324-34.
33. Palcic B, Lam S, Hung J, MacAulay C. Detection and localization of early lung cancer by imaging techniques. Chest 1991; 99: 742-3.
34. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88: 183-92.
35. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954; 8: 1-12.
36. Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer 1953; 7: 68-72.
37. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
38. Sakamoto H, Shimizu J, Horio Y, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007; 212: 287-94.
39. Brody JP. Parallel routes of human carcinoma development: implications of the age-specific incidence data. PLoS One 2009; 4: e7053.
40. Wistuba II, Behrens C, VirmaniAK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-60.
41. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
42. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002; 94: 1023-31.
43. Shibuya K, Nakajima T, Fujiwara T, et al. Narrow band imaging with highresolution bronchovideoscopy: a new approach for visualizing angiogenesis in squamous cell carcinoma of the lung. Lung Cancer 2010; 69: 194-202.
44. Mascaux C, Martin B, Verdebout JM, et al. COX-2 expression during early lung squamous cell carcinoma oncogenesis. Eur Respir J 2005; 26: 198-203.
45. Nicholson AG, Perry LJ, Cury PM, et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001; 38: 202-8.
46. Alaa M, Shibuya K, Fujiwara T, et al. Risk of lung cancer in patients with preinvasive bronchial lesions followed by autofluorescence bronchoscopy and chest computed tomography. Lung Cancer 2011; 72: 303-8.
47. McCaughan F, Pipinikas CP, Janes SM, et al. Genomic evidence of preinvasive clonal expansion, dispersal and progression in bronchial dysplasia. J Pathol 2011; 224: 153-9.
48. Lee SH, Park BJ. p53 activation by blocking Snail: a novel pharmacological strategy for cancer. Curr Pharm Des 2011; 17: 610-7.
49. Giangreco A, Lu L, Vickers C, et al. beta-Catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition. J Pathol 2012; 226: 575-87.
50. Baua (German Federal Institute for Occupational Safety and Health). Liste der Berufskrankheiten. (German.) Cited Nov 2012. http://www.baua.de/de/ Publikationen/Faltblaetter/F3.pdf;jsessionid=4A7941C030ED362F186D2-FE0166CB839. 1-cid246?-blob=publicationFile&v=9.
51. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
52. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6: 1496-504.
53. Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000; 83: 632-6.
54. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29: 23-36.
55. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002; 26: 767-73.
56. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 2008; 68: 2106-11.
57. Bubendorf L. Preneoplastic lesions of pulmonary carcinoma. (German.) Pathologe 2011; 32 (Suppl 2): 218-23.
58. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65: 7568-72.
59. Tang X, Varella-Garcia M, Xavier AC, et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) 2008; 1: 192-200.
60. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29: 49-60.
61. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-6.
62. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-20.
63. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
64. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2012; 6: 244-85.
65. Aguayo SM, Miller YE, Waldron JA Jr et al. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 1992; 327: 1285-8.
66. Warth A, Herpel E, Schmahl A, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in association with an adenocarcinoma: a case report. J Med Case Rep 2008; 2: 21.
67. Fox M, Van Berkel V, Bousamra M 2nd, et al. Surgical management of pulmonary carcinoid tumors: sublobar resection versus lobectomy. Am J Surg 2012; 96: 412-6.
68. Wistuba II, Berry J, Behrens C, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000; 6: 2604-10.
69. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28: 3-13.
70. Kao SC, Reid G, van Zandwijk N, et al. Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 2011; 43: 201-12.
71. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2012; 136: 1217-26.
72. Galateau-Sallé F, editor. Pathology of Malignant Mesothelioma. London: Springer, 2006.
73. Hammar SP, Henderson DW, Klebe S, Dodson RF. Neoplasms of the pleura. In: Tomashefski JF Jr. Dail and Hammar's Pulmonary Pathology. New York: Springer, 2008, 558-734.
74. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2012; 127: 2870-8.
75. Patnaik SK, Yendamuri S, Kannisto E, et al. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One 2012; 7: e46045.
76. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2012; 108: 3713-8.
77. GaoW, Lu X, Liu L, et al. MiRNA-21: a biomarker predictive for platinumbased adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012; 13: 330-40.
78. Higgins G, Roper KM, Watson IJ, et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci USA 2012; 109: E3128-35.